Elevance Health Q4 revenues hit $45 billion, driven by premium growth and acquisitions. 2025 EPS guidance is $34.15-$34.85, with a $1.71 dividend declared.
Barclays raised the firm’s price target on Elevance Health (ELV) to $512 from $501 and keeps an Overweight rating on the shares post the Q4 ...
The GreensKeeper Value Fund finished the year 2024 +23.6% net of fees and expenses. Click here to read the full fund letter.